Cardiovasular disease, kidney disease, diabetes type 2 Cardiovascular disease, kidney disease, diabetes
Conditions
Interventions
Two medical devices will be used in the home-based screening phase of this study. These devices are CE-marked and will be used according to their intended use. 
- PeeSpot urine collection device: The PeeSpot urine collection device consists of a holder containing a urine absorption pad in a transport tube. The urine absorption pad is an absorption felt contai
- Happitech SDK: With the Happitech software, participants monitor their heart rate and heart rate variability with use of photoplethysmography (PPG) and powered by AI algorithms. PPG is a non-invasiv
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: age 50-75 years living in one of the four participating regions in the Netherlands
Exclusion criteria
Exclusion criteria: age 75 years living outside the participating regions being institutionalized having participated in the previously conducted THOMAS Study (NL65228.042.18, METc 2018/687)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall effectiveness of population based screening on atrial fibrillation and chronic kidney disease (defined by elevated albuminuria) in subjects aged 50-75 years, based on: - Participation rate of different screening strategies and phases - Yield of the screening (number of subjects with (newly) diagnosed disease and risk factors) - Effectiveness of the different screening and treatment strategies on the main (combined) endpoint (as defined in protocol section 10.1), compared to standard care | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall effectiveness of population based screening on heart failure, coronary artery disease, and diabetes type 2 in subjects aged 50-75 years, based on: - Effectiveness of different screening and treatment strategies on other cardiovascular events, compared to standard care - Cost-effectiveness of different screening strategies, compared to standard care - Safety of the atrial fibrillation screening and treatment program, compared to standard care | — |
Countries
Netherlands
Contacts
Public ContactL.M. Kieneker
Universitair Medisch Centrum Groningen
Outcome results
None listed